SAFC Pharma, a member of the Sigma-Aldrich Group, has been appointed by Affichem to provide chemical development services relating to Dendrogenine A, a new first-in-class molecule currently in preclinical development for the potential treatment of aggressive cancers. This compound contains an original mechanism of action, which makes tumor-producing, tumor-specific antigens and activates the cytotoxic T response against the tumor through the stimulation of the monocyte differentiation into “dend...